View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 11, 2017updated 11 Jul 2022 9:56am

SMC approves daratumumab for myeloma patients in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The drug is currently being jointly developed by Genmab and Johnson & Johnson subsidiary Janssen Biotech, which has procured worldwide commercialisation rights to the treatment from Genmab.

Daratumumab is the first new immunotherapy drug that has been approved for the treatment of patients with myeloma in the UK.

It belongs to a group of medicines known as monoclonal antibodies and works by using the patient’s own immune system to combat myeloma cells in order to either kill them or stop them from growing.

Approved as a monotherapy, the drug can be used as a fourth line treatment option for patients with relapsed and/or refractory myeloma, whose prior treatment has included a proteasome inhibitor drug, such as bortezomib (Velcade), and an immunomodulatory drug, such as lenalidomide (Revlimid).

The treatment can also be used on patients who have demonstrated disease progression on their last treatment.

“Daratumumab is an exciting and innovative new treatment which has been shown to have a very beneficial effect on length of remission in patients who respond.”

Myeloma UK chief executive Rosemarie Finley said: “This is great news for myeloma patients in Scotland and their families.

“Daratumumab is an exciting and innovative new treatment which has been shown to have a very beneficial effect on length of remission in patients who respond.

“Despite the welcome approval of new drugs in recent years, there is still an urgent need for new myeloma treatments; especially for relapsed patients who have exhausted other standard treatment options. Today’s approval gives myeloma patients whose cancer has come back an important new treatment option.”

Myeloma UK is the only organisation in the country that focuses on dealing with myeloma.


Image: Daratumumab injection. Photo: courtesy of Myeloma UK.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology